APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear
Sino Bio got fourth indication approval for Benmelstobart plus Anlotinib. Wuxi Biologics’ three facilities got Korean GMP certification. FDA...
351 Views
Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins
​US Paracetamol prices surged 24.6% in March 2026 due to Chinese supply pullback, Indian FDA alerts, and rising costs, impacting Indian API-heavy...
268 Views
Pharmaceuticals: US tariffs on branded drugs, generics exempted
We believe the key motive behind tariffs is to push the innovator company toward MFN or investment in plants/R&D to bring down drug prices.
163 Views
APAC Healthcare Weekly (January 18) – ImmuneOnco, Wuxi Bio, Eisai, Daiichi, SK Biopharm, HK Inno.N
ImmuneOnco got trial approval for atherosclerosis drug candidate, timdarpacept in China. Eisai secures rights to NSCLC drug taletrectinib. HK inno...
411 Views
Pharmaceuticals: Indian CRDMOs at a pivotal point, scale-up key
The Indian Contract Research, Development, and Manufacturing Organizations (CRDMO) market is poised to grow rapidly at a CAGR of ~13.4% over 2024...
190 Views